Deborah Ashby
Overview
Explore the profile of Deborah Ashby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
5574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ursino M, Villacampa G, Rekowski J, Dimairo M, Solovyeva O, Ashby D, et al.
EClinicalMedicine
. 2025 Jan;
79:102988.
PMID: 39877554
Funding: This work is a further extension of the SPIRIT-DEFINE study, which obtained no external funding. The principal investigator (CY) used internal staff resources, together with additional resources from external...
2.
Rekowski J, Guo C, Solovyeva O, Dimairo M, Rouhifard M, Patel D, et al.
EClinicalMedicine
. 2025 Jan;
79:102987.
PMID: 39877553
Funding: This work is a further extension of the CONSORT-DEFINE study, which was funded by the UK Medical Research Council (MRC)-National Institute for Health and Care Research (NIHR) Methodology Research...
3.
Atchison C, Gilby N, Pantelidou G, Clemens S, Pickering K, Chadeau-Hyam M, et al.
JMIR Public Health Surveill
. 2025 Jan;
11:e60022.
PMID: 39791251
Background: High response rates are needed in population-based studies, as nonresponse reduces effective sample size and bias affects accuracy and decreases the generalizability of the study findings. Objective: We tested...
4.
Pocock S, Owen R, Gregson J, Mt-Isa S, Baumgartner R, Ashby D, et al.
J Thromb Haemost
. 2024 Jan;
22(5):1399-1409.
PMID: 38280725
Background: A treatment's overall favorable benefit-risk profile does not imply that every individual patient will benefit from the treatment. Objectives: To describe a statistical methodology for quantifying the benefit-risk trade-off...
5.
Yap C, Solovyeva O, de Bono J, Rekowski J, Patel D, Jaki T, et al.
BMJ
. 2023 Oct;
383:e076387.
PMID: 37863501
No abstract available.
6.
Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, et al.
BMJ
. 2023 Oct;
383:e076386.
PMID: 37863491
No abstract available.
7.
Ward H, Atchison C, Whitaker M, Davies B, Ashby D, Darzi A, et al.
Am J Public Health
. 2023 Sep;
113(11):1201-1209.
PMID: 37733993
The UK Department of Health and Social Care funded the REal-time Assessment of Community Transmission-2 (REACT-2) study to estimate community prevalence of SARS-CoV-2 IgG (immunoglobulin G) antibodies in England. We...
8.
Whitaker M, Davies B, Atchison C, Barclay W, Ashby D, Darzi A, et al.
Nat Commun
. 2023 Aug;
14(1):4957.
PMID: 37587102
The value of SARS-CoV-2 lateral flow immunoassay (LFIA) tests for estimating individual disease risk is unclear. The REACT-2 study in England, UK, obtained self-administered SARS-CoV-2 LFIA test results from 361,801...
9.
Eales O, Haw D, Wang H, Atchison C, Ashby D, Cooke G, et al.
PLoS Biol
. 2023 May;
21(5):e3002118.
PMID: 37228015
The relationship between prevalence of infection and severe outcomes such as hospitalisation and death changed over the course of the COVID-19 pandemic. Reliable estimates of the infection fatality ratio (IFR)...
10.
Elliott P, Whitaker M, Tang D, Eales O, Steyn N, Bodinier B, et al.
Am J Public Health
. 2023 Mar;
113(5):545-554.
PMID: 36893367
The REal-time Assessment of Community Transmission-1 (REACT-1) Study was funded by the Department of Health and Social Care in England to provide reliable and timely estimates of prevalence of severe...